cadonilimab
mAbexperimentalMulti-specific
Clinical trial activity
193 trials · 70 clinical orgs · 0 marketing orgs
Phase 1
39
Phase 2
174
Phase 3
16
Phase 4
0
Earliest trial started Jan 18, 2019 (NCT03852251)
Timeline
Indications
Studied for
- Adenoma, Bile Duct · Phase 2
- Antibodies, Bispecific · Phase 3
- Antibodies, Monoclonal · Phase 2
- Bile Duct Neoplasms · Phase 2
- Biliary Tract Neoplasms · Phase 2
- Brain Neoplasms · Phase 2
- Breast Neoplasms · Phase 2
- Capecitabine · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Hepatocellular · Phase 3
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Renal Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 2
- Chemotherapy, Adjuvant · Phase 3
- Cholangiocarcinoma · Phase 2
- Colorectal Neoplasms · Phase 3
- DNA Mismatch Repair · Phase 2
- Drug Evaluation · Phase 3
- Drug Misuse · Phase 2
- Drug Therapy · Phase 3
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 3
- Esophageal Squamous Cell Carcinoma · Phase 2
- General Surgery · Phase 2
- Glioblastoma · Phase 1
- Healthy Volunteers · Phase 1
- Hysterectomy · Phase 2
- Immune Checkpoint Inhibitors · Phase 1/Phase 2
- Immunotherapy · Phase 2
- Irinotecan · Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 2
- Lung Neoplasms · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 1/Phase 2
- Melanoma · Phase 2
- Mesothelioma · Phase 2
- Microsatellite Instability · Phase 2
- Mouth Neoplasms · Phase 2
- Mutation · Phase 2
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 3
- Neoadjuvant Therapy · Phase 3
- Neoplasm Metastasis · Phase 2
- Neoplasm Recurrence, Local · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 3
- Oxaliplatin · Phase 2
- Pancreatic Neoplasms · Phase 2
- Peritoneal Neoplasms · Phase 2
- Radiosurgery · Phase 2
- Rectal Neoplasms · Phase 2
- Safety · Phase 3
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 3
- Triple Negative Breast Neoplasms · Phase 2
- Urinary Bladder Neoplasms · Phase 2
- Urologic Neoplasms · Phase 2
- Uterine Cervical Neoplasms · Phase 3
- Vulvar Neoplasms · Phase 2
Mechanism of action
- Cytotoxic T-lymphocyte protein 4INHIBITOR
Cytotoxic T-lymphocyte protein 4 inhibitor
- Programmed cell death protein 1INHIBITOR
Programmed cell death protein 1 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594456 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07263919 | Phase 2 | Dec 31, 2025 | Akeso Pharmaceuticals, Inc., People's Liberation Army of China |
| NCT07243951 | Phase 2 | Nov 28, 2025 | Fudan University |
| NCT07245446 | Phase 2 | Oct 29, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT07023315 | Phase 3 | Jul 31, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT07052253 | Phase 2 | Jul 25, 2025 | Akeso Pharmaceuticals, Inc., TransThera Biosciences Co., Ltd |
| NCT06913218 | Phase 1 | Jul 22, 2025 | Akeso Pharmaceuticals, Inc., Fudan University |
| NCT06984718 | Phase 2 | Jun 25, 2025 | Akeso Pharmaceuticals, Inc., Fudan University |
| NCT07003022 | Phase 2 | Jun 1, 2025 | Fudan University |
| NCT06949033 | Phase 3 | May 15, 2025 | LanZhou University |
| NCT06851104 | Phase 2 | May 1, 2025 | Guangxi Medical University |
| NCT06946836 | Phase 2 | Apr 21, 2025 | Huazhong University of Science and Technology |
| NCT06940921 | Phase 1/Phase 2 (Phase 2) | Mar 20, 2025 | Akeso Pharmaceuticals, Inc., Chongqing Medical University |
| NCT06878196 | N/A | Mar 10, 2025 | Fudan University |
| NCT07104149 | Phase 2 | Mar 10, 2025 | Henan Provincal People's Hospital, Zhengzhou University |
| NCT06789848 | Phase 2 | Feb 18, 2025 | Akeso Pharmaceuticals, Inc., The University of Texas, Dallas |
| NCT06769971 | Phase 2 | Feb 1, 2025 | Sichuan University |
| NCT06715501 | N/A | Dec 1, 2024 | Ningbo No. 1 Hospital, Ningbo University |
| NCT06670300 | Phase 2 | Dec 1, 2024 | Henan Medical University |
| NCT06646055 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2024 | Akeso Pharmaceuticals, Inc. |
| NCT06654011 | Phase 2 | Nov 1, 2024 | Huazhong University of Science and Technology |
Showing 20 of 193 trials
Page 1 / 10
Organizations
Research & Development (70)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 58 | 45 | 3 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 27 | 15 | 3 | 2020 |
| Sun Yat-Sen University | Academic/Hospital | 26 | 19 | 3 | 2019 |
| Fudan University | Academic/Hospital | 19 | 13 | 4 | 2021 |
| Huazhong University of Science and Technology | Academic/Hospital | 14 | 14 | 2 | 2023 |
| Tianjin Medical University | Academic/Hospital | 11 | 9 | 2 | 2022 |
| Sichuan University | Academic/Hospital | 9 | 8 | 1 | 2023 |
| Zhejiang University | Academic/Hospital | 9 | 5 | 2 | 2021 |
| Central South University | Academic/Hospital | 7 | 3 | 1 | 2021 |
| Jiao Tong University | Academic/Hospital | 7 | 5 | 1 | 2022 |
| Fujian Medical University | Academic/Hospital | 5 | 4 | 1 | 2023 |
| Henan Medical University | Academic/Hospital | 5 | 4 | 2 | 2022 |
| Peking University | Academic/Hospital | 5 | 4 | 3 | 2020 |
| People's Liberation Army of China | Government | 5 | 1 | 1 | 2020 |
| Anhui Medical University | Academic/Hospital | 3 | 1 | 2 | 2023 |
| Eastern Hepatobiliary Surgery Hospital | Academic/Hospital | 3 | 2 | 1 | 2022 |
| Guangzhou Medical University | Academic/Hospital | 3 | 3 | 1 | 2023 |
| Harbin Medical University | Academic/Hospital | 3 | 2 | 1 | 2023 |
| Shandong University | Academic/Hospital | 3 | 1 | 2 | 2024 |
| Shengjing Hospital | Academic/Hospital | 3 | 2 | 2 | 2024 |
70 organizations
Page 1 / 4